Disseminated intravascular coagulation

Hematology Journal

Volumn 4, Issue 5, 2003, Pages 295-302

  Slofstra, Sjoukje H ^a   Spek, C Arnold ^a   ten Cate, Hugo ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Disseminated intrasvascular coagulation; Pathophysiology; Shwartzman

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; BLOOD CLOTTING INHIBITOR; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PROCOAGULANT; THROMBOPLASTIN;

BLEEDING; BLOOD CLOTTING; BLOOD VESSEL INJURY; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; GRAM NEGATIVE SEPSIS; GRANULOCYTE FUNCTION; HUMAN; HYPERCOAGULABILITY; INFLAMMATION; LEUKOCYTE ACTIVATION; MOLECULAR INTERACTION; MULTIPLE ORGAN FAILURE; PATHOPHYSIOLOGY; REVIEW; SHWARTZMAN PHENOMENON;

BLOOD COAGULATION; DISSEMINATED INTRAVASCULAR COAGULATION; FIBRINOLYSIS; GRANULOCYTES; HUMANS; INFLAMMATION; PROGNOSIS;

EID: 0141994810     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200263     Document Type: Review

References (100)

1. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Eng J Med 1999; 341: 586-592.
2. Taylor FBJ, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86: 1327-1330.
3. Kramer J, Otten HM, Levi M, ten Cate H. The association of disseminated intravascular coagulation with specific diseases. Reanimation 2002; 11: 575-583.
4. Jansen PM, Eisele B, de Jong IW, Chang A, Delvos U, Taylor FB Jr, Hack CE. Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J Immunol 1998; 160: 475-484.
5. Welty-Wolf KE, Carraway MS, Miller DL et al. Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med 2001; 164: 1988-1996.
6. Kremer Hovinga JA, Otten JMM, Levi MM, ten Cate H. Disease specific mechanisms of disseminated intravascular coagulation. In: ten Cate H, Levi M (eds). Molecular Mechanisms of Disseminated Intravascular Coagulation; Eurekah.com, Landes Bioscience, Georgetown, Texas 2003.
7. Hardaway RM, McKay DG. Production of lower nephrosis in dogs by means of an episode of intravascular clotting. Surg Forum 1959; IX: 134-137.
8. Hardaway RM, McKay DG. Intravasular thrombi and the intestinal factor of irrevessible shock. Ann Surg 1959; 150: 161-165.
9. Hardaway RM, McKay DG, Wade GH. Pathologic study of intravascular coagulation following incompatible blood transfusion in dogs. Am J Surg 1956; 91: 24-40.
10. Hardaway RM, McKay DG. Production of acute hemorrhagic pancreatitis in dogs by means of an episode of DIC. Surgery 1959; 45: 557-561.
11. Hardaway RM. Disseminated intravascular coagulation syndromes. Arch Surg 1961; 83: 842-850.
12. Archer LT. Pathologic manifestations of septic shock. In: Proctor RA (ed.) Handbook of Endotoxin. Elsevier Science: Amsterdam, 1986, p. 18-54.
13. Movat HZ, Wasi S. Severe microvascular injury induced by lysosomal releasates of human polymorphonuclear leukocytes. Increase in vasopermeability, hemorrhage, and microthrombosis due to degradation of subendothelial and perivascular matrices. Am J Pathol 1985; 121: 404-417.
14. Thomas L, Good RA. Studies on the Generalized Shwartzman Reaction. I. General observations concerning the phenomenon. J Exp Med 1952; 96: 605-624.
15. Lee SY, Chang SK, Lee IH, Kim YM, Chung SI. Depletion of plasma factor XIII prevents disseminated intravascular coagulation-induced organ damage. Thromb Haemost 2001; 85: 464-469.
16. Koide N, Abe K, Narita K et al. Apoptotic cell death of vascular endothelial cells and renal tubular cells in the generalized Shwartzman reaction. FEMS Immunol Med Microbiol 1996; 16: 205-211.
17. Koide N, Narita K, Kato Y et al. Expression of Fas and Fas ligand on mouse renal tubular epithelial cells in the generalized shwartzman reaction and its relationship to apoptosis. Infect Immun 1999; 67: 4112-4118.
18. Ozmen L, Pericin M, Hakimi J et al. Interleukin 12, interferon gamma, and tumor necrosis factor alpha are the key cytokines of the generalized Shwartzman reaction. J Exp Med 1994; 180: 907-915.
19. Niemetz J, Fani K. Role of leukocytes in blood coagulation and the generalized Shwartzman reaction. Nat - New Biol 1971; 232: 247-248.
20. Muller-Berghaus G, Eckhardt T. The role of granulocytes in the activation of intravascular coagulation and the precipitation of soluble fibrin by endotoxin. Blood 1975; 45: 631-641.
21. Koide N, Abe K, Narita K et al. Expression of intercellular adhesion molecule-1 (ICAM-1) on vascular endothelial cells and renal tubular cells in the generalized Shwartzman reaction as an experimental disseminated intravascular coagulation model. FEMS Immunol Med Microbiol 1997; 18: 67-74.
22. Sunderkotter C, Seeliger S, Schonlau F et al. Different pathways leading to cutaneous leukocytoclastic vasculitis in mice. Exp Dermatol 2001; 10: 391-404.
23. Toh H, Miyata T, Torisu M. Characterization of neutrophil activation by repeated injection of endotoxin in rabbits. Role of neutrophils in the generalized Shwartzman reaction. J Leukocyte Biol 1993; 53: 256-263.
24. Brozna JP. Shwartzman reaction. Semin Thromb Hemost 1990; 16: 326-332.
25. Norman KE, Cotter MJ, Stewart JB, Abbitt KB, Ali M, Wagner BE et al. Combined anticoagulant and antiselectin treatments prevent lethal intravascular coagulation. Blood 2003; 101: 921-928.
26. Colucci M, Balconi G, Lorenzet R et al. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983; 71: 1893-1896.
27. van der Poll T, Buller HR, ten Cate H et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Eng J Med 1990; 322: 1622-1627.
28. Higure A, Okamoto K, Hirata K et al. Macrophages and neutrophils infiltrating into the liver are responsible for tissue factor expression in a rabbit model of acute obstructive cholangitis. Thromb Haemost 1996; 75: 791-795.
29. Todoroki H, Higure A, Okamoto K, Okazaki K, Nagafuchi Y, Takeda S, et al. Possible role of platelet-activating factor in the in vivo expression of tissue factor in neutrophils. J Surg Res 1998; 80: 149-155.
30. Todoroki H, Nakamura S, Higure A, Okamoto K, Takeda S, Nagata N et al. Neutrophils express tissue factor in a monkey model of sepsis. Surgery 2000; 127: 209-216.
31. de Waard V. Activation mechanisms in vascular disease. PhD thesis, UvA, Amsterdam, 2002.
32. Goel MS, Diamond SL. Neutrophil enhancement of fibrin deposition under flow through platelet-dependent and -independent mechanisms. Arterioscler Thromb Vasc Biol 2001; 21: 2093-2098.
33. Pu Q, Wiel E, Corseaux D et al. Beneficial effect of glycoprotein IIb/IIIa inhibitor (AZ-1) on endothelium in Escherichia coli endotoxin-induced shock. Crit Care Med 2001; 29: 1181-1188.
34. Nieuwland R, Berckmans RJ, McGregor S et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000; 95: 930-935.
35. Muller I, Klocke A, Alex M et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J 2003; 17: 476-478.
36. Esmon CT, Ding W, Yasuhiro K et al. The protein C pathway: new insights. Thromb Haemost 1997; 78: 70-74.
37. Camerer E, Kolsto AB, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 1996; 81: 1-41.
38. Edgington TS, Mackman N, Fan ST, Ruf W. Cellular immune and cytokine pathways resulting in tissue factor expression and relevance to septic shock. Nouv Rev Francaise d' Hematol 1992; 34(Suppl): S15-S27.
39. Levi M, ten Cate H, Bauer KA et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114-120.
40. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Eng J Med 1999; 340: 1555-1564.
41. Biemond BJ, Levi M, Ten Cate H et al. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Sci 1995; 88: 587-594.
42. Montes R, Rodriguez-Whilhelmi P, Hurtado V et al. The endotoxin-induced plasminogen activator inhibitor-1 increase in rabbits is not tumor necrosis factor-alpha dependent and can occur in the absence of interleukin-1 beta. Thromb Haemost 2002; 88: 639-643.
43. Imamura T, Kaneda H, Nakamura S. New functions of neutrophils in the arthus reaction: expression of tissue factor, the clotting initiator, and fibrinolysis by elastase. Lab Invest 2002; 82: 1287-1295.
44. Moir E, Robbie LA, Bennett B, Booth NA. Polymorphonuclear leucocytes have two opposing roles in fibrinolysis. Thromb Haemost 2002; 87: 1006-1010.
45. Bach-Gansmo ET, Halvorsen S, Godal HC, Skjonsberg OH. Impaired clot lysis in the presence of human neutrophil elastase. Thromb Res 1995; 80: 153-159.
46. Matthay MA. Severe sepsis - a new treatment with both anticoagulant and antiinflammatory properties (letter; comment). N Eng J Med 2001; 344: 759-762.
47. Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Therap 2002; 300: 729-735.
48. Johnson K, Choi Y, DeGroot E, Samuels I, Creasey A, Aarden L. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J Immunol 1998; 160: 5130-5135.
49. Lorant DE, Topham MK, Whatley RE et al. Inflammatory roles of P-selectin. J Clin Invest 1993; 92: 559-570.
50. Cunningham MA, Romas P, Hutchinson P, Holdsworth SR, Tipping PG. Tissue factor and factor VIIa receptor/ ligand interactions induce proinflammatory effects in macrophages. Blood 1999; 94: 3413-3420.
51. Randolph GJ, Luther T, Albrecht S, Magdolen V, Muller WA. Role of tissue factor in adhesion of mononuclear phagocytes to and trafficking through endothelium in vitro. Blood 1998; 92: 4167-4177.
52. Heine H, Ulmer AJ, Flad HD, Hauschildt S. Lipopolysaccharide-induced change of phosphorylation of two cytosolic proteins in human monocytes is prevented by inhibitors of ADP-ribosylation. J Immunol 1995; 155: 4899-4909.
53. Beyaert R, Cuenda A, Vanden Berghe W et al. The p38/ RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J 1996; 15: 1914-1923.
54. Altieri DC. Leukocyte interaction with protein cascades in blood coagulation. Curr Opin Hematol 1995; 2: 41-46.
55. Marlar RA, Endres-Brooks J, Miller C. Serial studies of protein C and its plasma inhibitor in patients with disseminated intravascular coagulation. Blood 1985; 66: 59-63.
56. Taylor Jr FB, Peer GT, Lockhart MS, Ferrell G, Esmon CT. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood 2001; 97: 1685-1688.
57. Taylor Jr FB, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987; 79: 918-925.
58. Taylor Jr FB, Stearns-Kurosawa DJ, Kurosawa S et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 2000; 95: 1680-1686.
59. Esmon CT. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 2001; 29: S48-S51.
60. de Fouw NJ, van Hinsbergh VW, de Jong YF, Haverkate F, Bettina RM. The interaction of activated protein C and thrombin with the plasminogen activator inhibitor released from human endothelial cells. Thromb Haemost 1987; 57: 176-182.
61. de Fouw NJ, de Jong YF, Haverkate F, Bertina RM. Activated protein C increases fibrin clot lysis by neutralization of plasminogen activator inhibitor - no evidence for a cofactor role of protein S. Thromb Haemost 1988; 60: 328-333.
62. Rezaie AR. Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. J Biol Chem 2001; 276: 15567-15570.
63. Yan SB, Dhainaut JF. Activated protein C versus protein C in severe sepsis. Crit Care Med 2001; 29: S69-S74.
64. Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Nat Acad Scie USA 1986; 83: 3460-3464.
65. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-745.
66. Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79: 124-130.
67. Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988; 8: 5588-5592.
68. Lentz SR, Tsiang M, Sadler JE. Regulation of thrombomodulin by tumor necrosis factor-alpha: comparison of transcriptional and posttranscriptional mechanisms. Blood 1991; 77: 542-550.
69. Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood 1990; 76: 2024-2029.
70. Faust SN, Levin M, Harrison OB et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis (see comments). N Eng J Med 2001; 345: 408-416.
71. Vervloet MG, Thijs LG, Hack CE. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost 1998; 24: 33-44.
72. Ishii K, Ito Y, Katagiri H, Matsumoto Y, Kakita A, Majima M. Neutrophil elastase inhibitor attenuates lipopolysaccharide-induced hepatic microvascular dysfunction in mice. Shock 2002; 18: 163-168.
73. Tkalcevic J, Novelli M, Phylactides M, Iredale JP, Segal AW, Roes J. Impaired immunity and enhanced resistance to endotoxin in the absence of neutrophil elastase and cathepsin G. Immunity 2000; 12: 201-210.
74. Taylor Jr FB, Chang AC, Peer GT et al. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood 1991; 78: 364-368.
75. Hesselvik JF, Blomback M, Brodin B, Maller R. Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome. Crit Care Med 1989; 17: 724-733.
76. Bredbacka S, Blomback M, Wiman B, Pelzer H. Laboratory methods for detecting disseminated intravascular coagulation (DIC): new aspects. Acta Anaesthesiol Scand 1993; 37: 125-130.
77. Lorente JA, Garcia-Frade LJ, Landin L et al. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993; 103: 1536-1542.
78. Asakura H, Ontachi Y, Mizutani T et al. An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation. Crit Care Med 2001; 29: 1164-1168.
79. Gando S, Kameue T, Nanzaki S, Nakanishi Y. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost 1996; 75: 224-228.
80. Watanabe R, Wada H, Miura Y et al. Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/ PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura. Clin Appl Thromb/Hemost 2001; 7: 229-233.
81. Gando S, Nakanishi Y, Tedo I. Cytokines and plasminogen activator inhibitor-1 in posttrauma disseminated intravascular coagulation: relationship to multiple organ dysfunction syndrome. Crit Care Med 1995; 23: 1835-1842.
82. Fukao H, Ueshima S, Okada K, Yamamoto K, Matsuo T, Matsuo O. Tissue-type plasminogen activator, type 1 plasminogen activator inhibitor and their complex in plasma with disseminated intravascular coagulation. Thromb Res 1992; 68: 57-65.
83. Hermans PW, Hibberd ML, Booy R et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 1999; 354: 556-560.
84. Leithauser B, Matthias FR, Nicolai U, Voss R. Hemostatic abnormalities and the severity of illness in patients at the onset of clinically defined sepsis. Possible indication of the degree of endothelial cell activation? Inten Care Med 1996; 22: 631-636.
85. Wada H, Mori Y, Okabayashi K et al. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients. Am J Hematol 2003; 72: 1-7.
86. Ueno H, Hirasawa H, Oda S, Shiga H, Nakanishi K, Matsuda K. Coagulation/fibrinolysis abnormality and vascular endothelial damage in the pathogenesis of thrombocytopenic multiple organ failure. Crit Care Med 2002; 30: 2242-2248.
87. Takahasi H, Urano T, Nagai N, Takada Y, Takada A. Neutrophil elastase may play a key role in developing symptomatic disseminated intravascular coagulation and multiple organ failure in patients with head injury. J Trauma-Injury Infect Crit Care 2000; 49: 86-91.
88. Feinstein DI. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood 1982; 60: 284-287.
89. Gillis S, Dann EJ, Eldor A. Low molecular weight heparin in the prophylaxis and treatment of disseminated intravascular coagulation in acute promyelocytic leukemia. Eur J Haematol 1995; 54: 59-60.
90. Audibert G, Lambert H, Toulemonde F et al. Utilisation d'une heparine de bas poids moleculaire, la CY 222, dans le traitement des coagulopathies de consommation. J Maladies Vase 1987; 12(Suppl B): 147-151.
91. Sakuragawa N, Hasegawa H, Maki M, Nakagawa M, Nakashima M. Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC) - a multicenter co-operative double-blind trial in comparison with heparin. Thromb Res 1993; 72: 475-500.
92. Levi M, de Jonge E, van der Poll T, ten Cate H. Disseminated intravascular coagulation. Thromb Haemost 1999; 82: 695-705.
93. Warren BL, Eid A, Singer P et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial (comment)(erratum appears in JAMA 2002;287192). JAMA 2001; 286: 1869-1878.
94. Doshi SN, Marmur JD. Evolving role of tissue factor and its pathway inhibitor. Crit Care Med 2002; 30: S241-S250.
95. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis (comment). N Eng J Med 2001; 344: 699-709.
96. Grinnell BW, Joyce D. Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis. Crit Care Med 2001; 29: S53-S60.
97. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 276: 11199-11203.
98. Minnema MC, Chang AC, Jansen PM et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000; 95: 1117-1123.
99. Randolph MM, White GL, Kosanke SD et al. Attenuation of tissue thrombosis and hemorrhage by ala-TFPI does not account for its protection against E. coli - a comparative study of treated and untreated non-surviving baboons challenged with LD100 E. coli. Thromb Haemost 1998; 79: 1048-1053.
100. Taylor Jr FB, Emerson Jr TE, Jordan R, Chang AK, Blick KE. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 1988; 26: 227-235.